Eli Lilly and Company (NYSE:LLY) expects 2025 revenue of between $58.0 billion – $61.0 billion. The midpoint demonstrates ~32% growth YoY, fueled by new Lilly medicines like Zepbound ...

Over the full year, Danaher generated $5.3 billion in free cash flow, achieving a free cash flow to net income conversion ... rapid adoption of Mounjaro and Zepbound. Eli Lilly also saw solid ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

Eli Lilly weight loss drug: Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. (Representative Image) Eli Lilly weight loss drug ...